Literature DB >> 11050913

Radiotherapy for hepatocellular carcinoma.

K Tokuuye1, M Sumi, Y Kagami, S Murayama, M Kawashima, H Ikeda, H Ueno, T Okusaka, S Okada.   

Abstract

PURPOSE: To retrospectively evaluate the effectiveness of radiotherapy with or without transarterial embolization (TAE) and/or percutaneous ethanol injection (PEI) in patients with hepatocellular carcinoma who were ineligible for surgery. PATIENTS AND METHODS: From October 1984 to November 1997, 62 patients underwent radiotherapy receiving 50 to 70 Gy in 25 to 35 treatments with or without transarterial embolization and/or percutaneous ethanol injection and were followed for a median period of 8.6 months (1.5 to 92 months).
RESULTS: Overall median survival rates were 9.5 months. Significant prognostic factors were the extent of pretreatment liver function impairment, radiation field size and the existence of tumor thrombosis. Six-month and 1-year local control rates were 67 and 54%, respectively. Seven of the 8 patients who suffered from hepatic failure had poor pretreatment liver functions.
CONCLUSION: Radiotherapy with or without transarterial embolization and/or percutaneous ethanol injection appears effective in controlling hepatocellular carcinoma and prolonged survival. Individualized treatment strategies are presented depending on the tumor presentation and the degree of liver function impairment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050913     DOI: 10.1007/pl00002348

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  9 in total

1.  Post-radiation survival time in hepatocellular carcinoma based on predictors for CT-determined, transarterial embolization and various other parameters.

Authors:  Ting-Kai Leung; Chi-Ming Lee; Li-Kuo Shen; Hsi-Chi Chen; Yu-Cheng Kuo; Jeng-Fong Chiou
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

2.  Enhancement of leukocyte adhesion after percutaneous irradiation in rats with hepatocellular carcinoma.

Authors:  Sasa-Marcel Maksan; Eduard Schmidt; Eduard Ryschich; Wolfgang Harms; Jan Schmidt
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

3.  RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma.

Authors:  G Z Gong; Y Yin; L G Xing; Y J Guo; T Liu; J Chen; J Lu; C Ma; T Sun; T Bai; G Zhang; R Wang
Journal:  Strahlenther Onkol       Date:  2012-02-08       Impact factor: 3.621

4.  [Personnel calculation in health care: intensive care and intermediate care units].

Authors:  W Plücker
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-10-15       Impact factor: 0.840

5.  Hepatic proliferation after partial liver irradiation in Sprague-Dawley rats.

Authors:  Zhi-Gang Ren; Jian-Dong Zhao; Ke Gu; Jian Wang; Guo-Liang Jiang
Journal:  Mol Biol Rep       Date:  2011-07-16       Impact factor: 2.316

6.  Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu; Lu-Ming Liu; Jie Li; Zhen Chen; Jun-Hua Lin; Zhi-Qiang Meng; Yi Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

7.  Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma.

Authors:  H Yoon; D Oh; H C Park; S W Kang; Y Han; D H Lim; S W Paik
Journal:  Strahlenther Onkol       Date:  2013-05-25       Impact factor: 3.621

8.  Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma.

Authors:  Yeon Seok Seo; Jin Nam Kim; Bora Keum; Sanghoon Park; Yong Dae Kwon; Yong Sik Kim; Yoon Tae Jeen; Hoon Jai Chun; Chul Yong Kim; Chang Duck Kim; Ho Sang Ryu; Soon Ho Um
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

9.  Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer.

Authors:  Chai Hong Rim; Sangjoon Park; Joong Yeol Woo; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2018-08-13       Impact factor: 3.621

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.